Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
CgPdr1p is a Candida glabrata Zn(2)-Cys(6) transcription factor involved in the regulation of the ABC-transporter genes CgCDR1, CgCDR2, and CgSNQ2, which are mediators of azole resistance. Single-point mutations in CgPDR1 are known to increase the expression of at least CgCDR1 and CgCDR2 and thus to contribute to azole resistance of clinical isolates. In this study, we investigated the incidence of CgPDR1 mutations in a large collection of clinical isolates and tested their relevance, not only to azole resistance in vitro and in vivo, but also to virulence. The comparison of CgPDR1 alleles from azole-susceptible and azole-resistant matched isolates enabled the identification of 57 amino acid substitutions, each positioned in distinct CgPDR1 alleles. These substitutions, which could be grouped into three different "hot spots," were gain of function (GOF) mutations since they conferred hyperactivity to CgPdr1p revealed by constitutive high expression of ABC-transporter genes. Interestingly, the major transporters involved in azole resistance (CgCDR1, CgCDR2, and CgSNQ2) were not always coordinately expressed in presence of specific CgPDR1 GOF mutations, thus suggesting that these are rather trans-acting elements (GOF in CgPDR1) than cis-acting elements (promoters) that lead to azole resistance by upregulating specific combinations of ABC-transporter genes. Moreover, C. glabrata isolates complemented with CgPDR1 hyperactive alleles were not only more virulent in mice than those with wild type alleles, but they also gained fitness in the same animal model. The presence of CgPDR1 hyperactive alleles also contributed to fluconazole treatment failure in the mouse model. In conclusion, this study shows for the first time that CgPDR1 mutations are not only responsible for in vitro/in vivo azole resistance but that they can also confer a selective advantage under host conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region) were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.](https://figures.cochat.ai/paper-figures/69b6baffc71c4842aa873ef304106b27/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-2.jpg)

![Figure 4 Effect of CgPDR1 expression on azole resistance. (A) Expression of CgPDR1 in a matched pair of azole-susceptible and azole-resistant isolates (DSY2235 and DSY2234), in revertant strains (“rev”) overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1Δ mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each strain (“DSY” for clinical strains and “rev” for revertant strains) were named according to their strain number origin. RNA was isolated from log phase cultures, slot-blotted to membranes, and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1 and substracted from background. Expression values represent the increase of CgPDR1 expression in revertant strains relative to the clinical isolates expressing the same CgPDR1 allele. (B) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235 and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and of a pdr1Δ mutant (SFY53). Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY2235 and DSY2234, in revertant strains (rev) overexpressing CgPDR1 alleles in a pdr1Δ mutant (SFY53). Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document (National Committee for Clinical Laboratory Standards, 2002).](https://figures.cochat.ai/paper-figures/ac16b99890e140cf9efad3769d9335b6/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-4.jpg)
![Figure 5 Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1Δ: SFY92; DSY565 pdr1Δ: SFY94; DSY562 pdr1Δ+562 (standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1Δ+565L280F (standing for re-introduction of CgPDR1 from DSY565 with L280F substitution): SFY115; DSY565pdr1Δ+562: SFY118; DSY565 pdr1Δ+565L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.](https://figures.cochat.ai/paper-figures/22fe62baf08b4a8880e792810b2a746e/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-5.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The authors also indicate that the altered cellular sterol composition of CG156 may affect intracellular signalling and trafficking pathways, as the efflux machinery [199,211,212] and any transport proteins that are proposed to mediate azole import via facilitated diffusion [213].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other cases of induced cross-resistance to azole drugs in C. glabrata were related to resistance against both azoles and amphotericin B [198,199,212] and related to prochloraz (an agricultural antifungal).”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BPY41 exhibited mitochondrial dysfunction”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“however, it is not dependent on the presence of GOF mutations in *CgPDR1* ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784 · cited 1×
“efflux pumps (for review, see [7]).”
Self-citationThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“mutations in genes involved in antibiotic resistance can be beneficial in the fitness of pathogenic bacteria [30,31].”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“The consensus motif is named PDRE (for pleiotropic drug resistance element) and is present in several ABC-transporter gene promoters such as PDR5, SNQ2 and YOR1 [25].”
BackgroundThe biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472 · cited 1×
“Restoration of fitness in drugresistant bacteria is often associated with the emergence of compensatory mutations [29].”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423 · cited 1×
“during patient treatment [4–6].”
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · cited 2×
“In bacteria, antimicrobial resistance is often associated with fitness costs and thus results in a competitive disadvantage against otherwise drug-susceptible bacteria within the host [28].”
BackgroundA nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343 · cited 1×
“. CgPdr1p acts as nuclear receptor by directly binding to diverse drugs and xenobiotics, such as azoles, to activate expression of efflux pumps genes resulting in multidrug resistance”
BackgroundSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 5×
“glabrata was performed as previously described [10].”
BackgroundMethodInfluentialSelf-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319 · cited 5×
“All primers and probes [13] were designed with Beacon Designer 2 (version 2.”
BackgroundMethodInfluentialSelf-citationD'Souza, C. A., Alspaugh, J. A., Yue, C., Harashima, T., Cox, G. M., Perfect, J. R., & Heitman, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3179-3191.2001 · Cited by 318
Vermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 3×
“cerevisiae [11].”
BackgroundKaur, R., Ma, B., & Cormack, B. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611195104 · Cited by 284
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247 · cited 3×
“glabrata clinical isolates and disruption of CgCDR1 or CgCDR1/CgCDR2 leads to hypersusceptibility to fluconazole, cycloheximide, and chloramphenicol [4,9,10,12,13].”
BackgroundMethodSelf-citationTsai, H.-F., Krol, A. A., Sarti, K. E., & Bennett, J. E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1384-1392.2006 · Cited by 237 · cited 9×
“Since enhanced CgPDR1 expression is observed in some petite mutants, it has been proposed that CgPDR1 regulates its own expression in response to mitochondrial dysfunction [15].”
BackgroundInfluentialPfaller, M. A., Messer, S. A., Boyken, L., Hollis, R. J., Rice, C., Tendolkar, S., & Diekema, D. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.008 · Cited by 234 · cited 1×
“treat due to the intrinsically low susceptibility of this species to azole drugs, especially to fluconazole [3].”
BackgroundVermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233 · cited 9×
“CgPDR1 deletion leads to a loss of CgCDR1 and CgCDR2 regulation and to a sharp increase in azole susceptibility [14].”
BackgroundInfluentialDelaveau, T., Delahodde, A., Carvajal, E., Subik, J., & Jacq, C. (1994) · Molecular and General Genetics MGG · doi:10.1007/bf00583901 · Cited by 217 · cited 1×
“Most GOF mutations in PDR3 map to the first two motifs of the inhibitory domain and to the transcriptional activation domain [23].”
BackgroundMechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 2×
“glabrata isolates with ABC transporter upregulation [4,13].”
BackgroundCarvajal, E., van den Hazel, H. B., Cybularz-Kolaczkowska, A., Balzi, E., & Goffeau, A. (1997) · Molecular and General Genetics MGG · doi:10.1007/s004380050584 · Cited by 173 · cited 1×
“In contrast, PDR1 mutations are scattered throughout the entire protein with some ‘‘hot spots’’ at the C-terminus [24].”
BackgroundIn Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model
Arendrup, M., Horn, T., & Frimodt-Møller, N. (2002) · Infection · doi:10.1007/s15010-002-2131-0 · Cited by 168 · cited 1×
“glabrata at varying doses (10(7) to 10(8) cells per mouse) with different immune system status (immunocompetent and immuno-suppressed) and in different mice backgrounds [37,38].”
BackgroundMarr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166 · cited 1×
“Other studies suggest that once the selective pressure eases, the fungal-resistant strains will disappear [34–36].”
BackgroundMiyazaki, H., Miyazaki, Y., Geber, A., Parkinson, T., Hitchcock, C., Falconer, D. J., Ward, D. J., Marsden, K., & Bennett, J. E. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1695 · Cited by 162 · cited 1×
“glabrata, the constitutive upregulated expression of ABC-transporter genes CgCDR1 and, to a lesser extent, CgCDR2 (also known as PDH1) plays a dominant role in azole resistance [4,8–11].”
BackgroundMarr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145 · cited 1×
“Other studies suggest that once the selective pressure eases, the fungal-resistant strains will disappear [34–36].”
BackgroundDelahodde, A., Delaveau, T., & Jacq, C. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4043 · Cited by 142 · cited 3×
“Most GOF mutations in PDR3 map to the first two motifs of the inhibitory domain and to the transcriptional activation domain [23].”
BackgroundTorelli, R., Posteraro, B., Ferrari, S., La Sorda, M., Fadda, G., Sanglard, D., & Sanguinetti, M. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06143.x · Cited by 141
Self-citationWarner, D. M., Folster, J. P., Shafer, W. M., & Jerse, A. E. (2007) · The Journal of Infectious Diseases · doi:10.1086/522964 · Cited by 128 · cited 1×
“. A few examples illustrate that mutations in genes involved in antibiotic resistance can be beneficial in the fitness of pathogenic bacteria”
BackgroundBrieland, J., Essig, D., Jackson, C., Frank, D., Loebenberg, D., Menzel, F., Arnold, B., DiDomenico, B., & Hare, R. (2001) · Infection and Immunity · doi:10.1128/iai.69.8.5046-5055.2001 · Cited by 117 · cited 1×
“glabrata at varying doses (10(7) to 10(8) cells per mouse) with different immune system status (immunocompetent and immuno-suppressed) and in different mice backgrounds [37,38].”
BackgroundCowen, L. E., Kohn, L. M., & Anderson, J. B. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.10.2971-2978.2001 · Cited by 113 · cited 1×
“However fitness is restored by further cultivation by still unknown compensatory mechanisms [33].”
BackgroundMultiple resistance mechanisms to azole antifungals in yeast clinical isolates
Sanglard, D., Ischer, F., Calabrese, D. R., de Micheli, M., & Billé, J. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80006-x · Cited by 106 · cited 1×
“glabrata cell extracts for immunoblotting were prepared by an alkaline extraction procedure as described previously [46].”
MethodSelf-citationMartins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1998) · Clinical Infectious Diseases · doi:10.1086/515006 · Cited by 103 · cited 1×
“Other studies suggest that once the selective pressure eases, the fungal-resistant strains will disappear [34–36].”
BackgroundGoffeau, A. (2008) · Nature · doi:10.1038/452541a · Cited by 90
In-vivo selection of an azole-resistant petite mutant of Candida glabrata
BOUCHARA, J.-P., LE BOUDOUIL, S., FILMON, R., ZOUHAIR, R., HALLET, J.-N., CHABASSE, D., RENIER, G., & DEFONTAINE, A. (2000) · Journal of Medical Microbiology · doi:10.1099/0022-1317-49-11-977 · Cited by 88
Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.5.2176-2179.2003 · Cited by 86 · cited 1×
“during patient treatment [4–6].”
Kamran, M., Calcagno, A.-M., Findon, H., Bignell, E., Jones, M. D., Warn, P., Hopkins, P., Denning, D. W., Butler, G., Rogers, T., et al. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.2.546-552.2004 · Cited by 75 · cited 1×
“glabrata mutants (such as ace2D) for which hypervirulence was associated with formation of pseudo-hyphae [39], the morphology of azole-resistant isolates tested here was not altered and therefore GOF mutations in CgPDR1 are likely to account for the observed phenotype.”
BackgroundGumbo, T., Drusano, G. L., Liu, W., Ma, L., Deziel, M. R., Drusano, M. F., & Louie, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00507-06 · Cited by 71 · cited 1×
“glabrata candidiasis [41–44].”
Isolation of a Candida glabrata centromere and its use in construction of plasmid vectors
Kitada, K., Yamaguchi, E., & Arisawa, M. (1996) · Gene · doi:10.1016/0378-1119(96)00132-1 · Cited by 70 · cited 1×
“To determine whether the two-fold increase in CgPDR1 expression observed in some isolates was sufficient to induce high levels of CgCdr1p and CgCdr2p and thus azole resistance, CgPDR1 alleles from an azole-susceptible and an azole-resistant matched isolate (DSY2235 and DSY2234, respectively) were cloned into the CEN-A…”
MethodFunction of Candida glabrata ABC transporter gene, PDH1
Izumikawa, K., Kakeya, H., Tsai, H., Grimberg, B., & Bennett, J. E. (2003) · Yeast · doi:10.1002/yea.962 · Cited by 67
Fluconazole versus Candida albicans : A Complex Relationship
Graybill, J. R., Montalbo, E., Kirkpatrick, W. R., Luther, M. F., Revankar, S. G., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2938 · Cited by 59 · cited 1×
“albicans by testing the virulence of azole-resistant isolates compared to their azole-susceptible parental isolate [32].”
BackgroundJu, J. Y., Polhamus, C., Marr, K. A., Holland, S. M., & Bennett, J. E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1240-1245.2002 · Cited by 48 · cited 2×
“Mice received daily intraperitoneal injections of 100 mg kg fluconazole diluted in saline [41] and the treatment was initiated 24 h after challenge and continued through post-infection day 7.”
MethodMacCallum, D. M., Findon, H., Kenny, C. C., Butler, G., Haynes, K., & Odds, F. C. (2006) · Infection and Immunity · doi:10.1128/iai.00817-06 · Cited by 45 · cited 1×
“In a second experiment, mice were rendered neutropenic as above described and were injected with 7610(7) CFUs of the strains [22].”
MethodCaspofungin in Combination with Amphotericin B against Candida glabrata
Barchiesi, F., Spreghini, E., Fothergill, A. W., Arzeni, D., Greganti, G., Giannini, D., Rinaldi, M. G., & Scalise, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2546-2549.2005 · Cited by 28 · cited 7×
“Results, which are expressed as CFUs per gram of tissue, represent means of values recorded separately for each of the ten mice.”
MethodInfluentialGygax, S. E., Vermitsky, J., Chadwick, S. G., Self, M. J., Zimmerman, J. A., Mordechai, E., Adelson, M. E., & Trama, J. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-08 · Cited by 25 · cited 1×
“glabrata [27].”
Mariné, M., Serena, C., Fernández-Torres, B., Pastor, F. J., & Guarro, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4757-4759.2005 · Cited by 17 · cited 1×
“glabrata candidiasis [41–44].”
Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole
Spreghini, E., Maida, C. M., Tomassetti, S., Orlando, F., Giannini, D., Milici, M. E., Scalise, G., & Barchiesi, F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00130-08 · Cited by 16 · cited 1×
“glabrata candidiasis [41–44].”
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“…expression patterns of the downstream effector genes, with the exception of increased expression of CDR1 and PUP1, and no correlation has been found between location of the mutation and altered gene expression (Tsai et al., 2006, 2010; Ferrari et al., 2009; Caudle et al., 2011; Paul et al., 2011).”
BackgroundAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
“glabrata, as well as loss of mitochondrial functions, not only mediate antifungal (azole) resistance but also enhance virulence in animal models [41–43].”
BackgroundMultidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
“The pleiotropic class of the ATP binding cassette (ABC) transporters (PDR) include the major azole drug transporters CDR1, CDR2 , and specifically for C. glabrata also the CgSNQ2 , and confer panazole resistance [40–42, 53].”
BackgroundMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Notably, only a few genes were commonly regulated by the GOF mutations, suggesting complex interactions of CgPDR1 with transcriptional machinery (Tsai et al. 2010; Caudle et al. 2011; Ferrari et al. 2011b).”
BackgroundInfluentialSelf-citationEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
“The CgPdr1p from the resistant isolates also had amino acid substitutions that conferred upregulation of CgPDR1 and azole resistance (93, 357).”
BackgroundInfluential
Metadata
- Authors
- Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- GATC Biotech (Germany) (DE)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Sanglard, Dominique
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-01-16
- Volume
- 5
- Issue
- 1
- Pages
- e1000268
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2607542
- OpenAlex
- W2133189384
- Cited by
- 295
- References
- 46
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 19 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 25 · 2017: 19 · 2016: 17 · 2015: 12 · 2014: 22 · 2013: 18 · 2012: 14
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, gain-of-function mutations, azole resistance, antifungal resistance, virulence, ABC transporters, transcription factors, clinical isolates, host fitness, trans-acting regulation
- MeSH terms
- Animals, Candidiasis, Female, Humans, Mice, Inbred BALB C, Mutation, Transcription Factors, Virulence, Fluconazole, Gene Expression Regulation, Fungal, ATP-Binding Cassette Transporters, Amino Acid Substitution, Drug Resistance, Fungal, Candida glabrata, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.